Domperidone

Phase 3Small molecule

Domperidone is a small molecule that works as a Dopamine D2 Receptor Antagonist.[2] It is being investigated across 16 indications, with its most advanced program in Phase 3.[1]

Domperidone is one of 462 small molecule programs targeting Premature Birth. It is currently in Phase 3.

Indications

Total Trials

Active Trials

461

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature BirthActive, not recruiting

GastroparesisActive, not recruiting

DyspepsiaActive, not recruiting

Parkinson DiseaseActive, not recruiting

Chronic Progressive Multiple SclerosisActive, not recruiting

GastroenteritisActive, not recruiting

Relapsing-Remitting Multiple SclerosisActive, not recruiting

Gastrointestinal DiseaseUnknown

Gastroesophageal Reflux DiseaseActive, not recruiting

Nausea and VomitingActive, not recruiting

Premature BirthPhase 2

Active, not recruiting

GastroparesisPhase 3

Active, not recruiting

DyspepsiaPhase 3

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Chronic Progressive Multiple SclerosisPhase 2

Active, not recruiting

GastroenteritisPhase 3

Active, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 2

Active, not recruiting

Gastrointestinal DiseasePreclinical

Unknown

Gastroesophageal Reflux DiseasePhase 3

Active, not recruiting

Nausea and VomitingPhase 3

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Domperidone

Johnson & Johnson

Phase 3

43 2

Aranesp

Amgen

Preclinical

40 3

Uloric

Takeda

Preclinical

3 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Sovaldi

Gilead

Preclinical

1 8

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Gastro-Intestinal Disorder

NCT01696734

Q3 2029

Phase 3Not yet recruiting

Delayed Gastric Emptying

NCT06695962

Q4 2035

N/ARecruiting

Gastroparesis

NCT04699591

Clinical

Trials by Indication[1]

Gastroparesis7 trials

Domperidone for Gastroparesis in Solid Organ Transplantation

Terminated·—·N/A·NCT00552422·6 enrolled

Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy

Available·—··NCT02494687

Treatment Use of Domperidone for Gastroparesis

No longer available·—··NCT02227927

Show 4 more trials

Compassionate Use of Domperidone for Refractory Gastroparesis

Recruiting·JJose Cocjin·N/A·NCT04699591·20 enrolled

Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis

Unknown status·LLiangzhou Wei·Phase 4·NCT02264587·60 enrolled

The Use of Domperidone for Gastroparesis

Withdrawn·AAllegiance Health·Phase 3·NCT01378884

Domperidone in Refractory Gastroparesis

Terminated·YYale University·Phase 2·NCT00760461·44 enrolled

Gastro-Intestinal Disorder5 trials

Domperidone for Refractory Gastrointestinal Disorders

Unknown status·—·N/A·NCT00777439·75 enrolled

Use of Domperidone for Treatment of Upper Gastrointestinal Disorders

No longer available·PPalo Alto Medical Foundation··NCT03128398

Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders

No longer available·PPrasanna K Kapavarapu··NCT02567175

Show 2 more trials

Domperidone for Relief of Gastrointestinal Disorders

Terminated·CCarle Physician Group·N/A·NCT00761254·42 enrolled

Domperidone in Treating Patients With Gastrointestinal Disorders

Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT01696734·200 enrolled

Nausea and vomiting3 trials

Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis

Completed·RRon Schey·N/A·NCT01711918·9 enrolled

Domperidone for Chronic Nausea and Vomiting

No longer available·YYehudith Assouline-Dayan··NCT02757534

A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02699385·10 enrolled

Dyspepsia3 trials

Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT03617016·160 enrolled

Clinical Trial for 'Shen Qu Xiao Shi' Oral Liquid in the Treatments of Children's Functional Dyspepsia

Completed·RRuijin Hospital·Phase 4·NCT05030116·356 enrolled

Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Completed·UUnknown Sponsor·Phase 3·NCT01355276·400 enrolled

Effectiveness2 trials

Effectiveness of Domperidone to Increase Breastmilk Supply in Mothers With Low Supply

Terminated·HHamilton Health Sciences Corporation·Phase 2·NCT00284024·45 enrolled

Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy

Unknown status·MMahidol University·N/A·NCT04104867·525 enrolled

22 more indications

Parkinson's Disease2 trials

Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00305331·25 enrolled

Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Completed·SSeoul National University Hospital·Phase 4·NCT03022201·40 enrolled

Preoperative1 trial

Study of Effects of Preoperative Oral Domperidone on Gastric Residual Volume After Clear Fluid Ingestion in Patients Scheduled for Elective Surgeries

Completed·—·Phase 3·NCT05570292·40 enrolled

Scleroderma1 trial

Gastroesophageal Reflux Treatment in Scleroderma

Completed·KKhon Kaen University·Phase 3·NCT01878526·80 enrolled

Multiple System Atrophy1 trial

Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Completed·—·Phase 1·NCT00103597·50 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)

Completed·UUniversity of Calgary·Phase 2·NCT02308137·64 enrolled

Low Level Laser Therapy1 trial

EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION

Completed·—·Phase 4·NCT03806062·60 enrolled

Gastrointestinal1 trial

The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms

No longer available·YYale University··NCT03810287

Newborns1 trial

Use of Domperidone to Increase Milk Production in Mothers With Newborns in Neonatology

Completed·HHospital de Clinicas de Porto Alegre·Phase 1·NCT03221855·30 enrolled

Not yet recruiting·UUniversity Hospital, Rouen·Phase 3·NCT06695962·70 enrolled

Cognitive Functions1 trial

The Impact of Air Travel on Passenger Cognitive Functions

Unknown status·DDinara Zhumanbayeva·Phase 2/3·NCT04802785·50 enrolled

Premature Infants1 trial

Effect of Domperidone on QT Interval in Premature Infants

Completed·NNantes University Hospital·Phase 2·NCT00238056

Treatment1 trial

Domperidone Expanded Access Treatment Program

No longer available·WWake Forest University Health Sciences··NCT04996134

Gastric Emptying1 trial

Effect of 10mg Domperidone on Gastric Emptying of a High-fat Meal and Appetite Sensations in Healthy Adults

Completed·—·N/A·NCT01347814·13 enrolled

Bowel Preparation1 trial

The Effect of Antiemetics on Bowel Preparation Before Colonoscopy

Unknown status·RRenJi Hospital·Phase 4·NCT04583111·200 enrolled

Cardiac Repolarization1 trial

Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02816853·44 enrolled

Pre-Term1 trial

Effect of Domperidone on the Nutrient Composition of Preterm Mother's Breast Milk

Completed·IIWK Health Centre·Phase 2/3·NCT00308334·46 enrolled

Endoscopy1 trial

Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy

Completed·—·N/A·NCT03662113·200 enrolled

Gastroenteritis1 trial

Symptomatic Treatment of Acute Gastroenteritis

Completed·IIRCCS Burlo Garofolo·Phase 3·NCT01257672·356 enrolled

Sudden Cardiac Death1 trial

Domperidone and Risk of Sudden Cardiac Death

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02500108·214,962 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)

Completed·UUniversity of Calgary·Phase 2·NCT02493049·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for Domperidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Domperidone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Domperidone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Dopamine D2 Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Domperidone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Q4 2035

Trials by Indication[1]

Gastroparesis7 trials

Gastro-Intestinal Disorder5 trials

Nausea and vomiting3 trials

Dyspepsia3 trials

Effectiveness2 trials

Parkinson's Disease2 trials

Preoperative1 trial

Scleroderma1 trial

Multiple System Atrophy1 trial

Secondary Progressive Multiple Sclerosis1 trial

Low Level Laser Therapy1 trial

Gastrointestinal1 trial

Newborns1 trial

Cardiac1 trial

Adverse Events1 trial

Delayed Gastric Emptying1 trial

Cognitive Functions1 trial

Premature Infants1 trial

Treatment1 trial

Gastric Emptying1 trial

Bowel Preparation1 trial

Cardiac Repolarization1 trial

Pre-Term1 trial

Endoscopy1 trial

Gastroenteritis1 trial

Sudden Cardiac Death1 trial

Relapsing-Remitting Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News